Key Events This Week
2 Feb: Stock opens at Rs.839.65, modest gain despite Sensex decline
3 Feb: Significant gap up and intraday high at Rs.887.55 (+4.65%)
4 Feb: Intraday low at Rs.812.85 amid sharp 7.32% decline
6 Feb: Strong rebound to Rs.849.00 (+4.66%) on robust quarterly results
Are Sai Life Sciences Ltd latest results good or bad?
2026-02-06 19:31:58Sai Life Sciences Ltd's latest financial results for Q3 FY26 reflect a significant operational turnaround, showcasing strong revenue growth and margin expansion. The company reported a net profit of ₹100.38 crores, which represents a year-on-year increase of 86.41%. Revenue for the quarter reached ₹556.46 crores, marking a 26.53% increase compared to the same period last year. This growth demonstrates robust demand for the company's contract research and manufacturing services. The operating margin, excluding other income, reached a record high of 33.76%, reflecting a substantial improvement from the previous year, driven by enhanced operational efficiency and scale advantages. Additionally, the profit after tax margin improved to 18.04%, indicating effective cost management and operational leverage. Quarter-on-quarter, the company also showed positive trends, with net profit climbing 19.73% from ₹83.84 c...
Read full news article
Sai Life Sciences Ltd Reports Robust Quarterly Growth Amid Positive Financial Trend
2026-02-06 16:00:38Sai Life Sciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, shifting from a very positive to a positive financial trend. The company’s latest results reveal robust revenue growth, margin expansion, and record profitability metrics, signalling a turnaround that has caught the attention of investors and analysts alike.
Read full news article
Sai Life Sciences Q3 FY26: Strong Momentum Continues But Valuation Concerns Persist
2026-02-06 09:48:02Sai Life Sciences Limited, a contract research and development organisation serving the pharmaceutical and biotechnology sectors, delivered a robust performance in Q3 FY26 (October-December 2025) with net profit surging 86.41% year-on-year to ₹100.38 crores, marking the company's strongest quarterly profit to date. The stock, currently trading at ₹841.05 with a market capitalisation of ₹17,765.60 crores, gained 3.68% following the results announcement, though it remains 14.49% below its 52-week high of ₹983.60.
Read full news article
Sai Life Sciences Ltd Hits Intraday Low Amid Price Pressure on 4 Feb 2026
2026-02-04 14:32:36Sai Life Sciences Ltd experienced a notable decline today, touching an intraday low of Rs 812.85, reflecting a sharp price correction of 7.49% amid heightened volatility and broader market dynamics.
Read full news article
Sai Life Sciences Ltd Opens Strong with Significant Gap Up on 3 Feb 2026
2026-02-03 10:11:12Sai Life Sciences Ltd commenced trading on 3 Feb 2026 with a significant gap up, opening 5.7% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start follows a series of gains and an upgrade in the company’s mojo grade, underscoring a shift in market perception.
Read full news article
Sai Life Sciences Ltd is Rated Hold
2026-01-31 10:10:48Sai Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Read full news articleWhen is the next results date for Sai Life Sciences Ltd?
2026-01-23 23:16:43The next results date for Sai Life Sciences Ltd is scheduled for 05 February 2026....
Read full news article
Sai Life Sciences Ltd is Rated Hold
2026-01-20 10:10:59Sai Life Sciences Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 08 Aug 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the company’s current position as of 20 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article





